Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.
about
T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyMild hemophilia A.Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional proteinMost factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia AImmune tolerance induction in haemophilia: evidence and the way forward.Joint protection in haemophilia.Surgery and inhibitor development in hemophilia A: a systematic review.Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.Outcomes in Patients With Hemophilia and von Willebrand Disease Undergoing Invasive or Surgical Procedures.Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.In silico analyses of missense mutations in coagulation factor VIII: identification of severity determinants of haemophilia A.T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.The natural history of mild haemophilia: a 30-year single centre experience.Risk of inhibitor development in mild haemophilia A increases with age.Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management.
P2860
Q30620098-B404B3BC-FDCD-4E3B-A1D5-4DA0A3F30D8CQ33608230-9A8A8189-97CF-4EAF-AE93-5EDA5878EAB3Q34416394-19B29139-261E-4626-907F-BB99A4A89CD0Q34614695-5A98889B-92C6-491B-9B02-E5B6D4773F1FQ34707266-8F6560CB-5A43-4451-8957-B91CF4A8181EQ35036998-577044D8-8154-4BA7-AC88-936EF17636F4Q35771007-4B4F9BC5-2FA9-4ACE-9E92-BA9DFC464F88Q36220085-9C65BCB1-1BAB-46F9-923B-D766D044BFA7Q37377945-B11582E2-F17E-4FDB-B56E-85383820BC07Q37903944-2A375203-5A4B-4F23-9060-E6049A6D2F71Q37912258-D514AAD3-ADF1-41EC-B6AA-6E8E54F35C0AQ37916686-80DA4686-E0C4-4771-8129-C500153D8270Q38241445-F75D1147-65F8-4B01-8D21-19F9F9B16B29Q38897517-8C2DB402-EC17-4E44-A5F5-E92DCD9146A3Q38944642-283FCBB1-C450-454C-8352-BD3B720DB291Q41100668-F2FAF69E-5C4B-4F92-874C-D42245F03B7BQ42381250-BD595B44-F83D-400F-97D3-9A40523F3081Q45871908-8DC50070-7508-4971-9C44-6404427ECE93Q45872598-4FDBE1D3-F981-4600-8B64-BDBAC9556383Q45878590-31021889-A916-4598-8F50-ED418106F958Q50065346-8A2D97C7-5182-4FF6-94A0-F3583CA7EE53
P2860
Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mild/moderate haemophilia A: n ...... sms and inhibitor development.
@en
Mild/moderate haemophilia A: n ...... sms and inhibitor development.
@nl
type
label
Mild/moderate haemophilia A: n ...... sms and inhibitor development.
@en
Mild/moderate haemophilia A: n ...... sms and inhibitor development.
@nl
prefLabel
Mild/moderate haemophilia A: n ...... sms and inhibitor development.
@en
Mild/moderate haemophilia A: n ...... sms and inhibitor development.
@nl
P2860
P1433
P1476
Mild/moderate haemophilia A: n ...... isms and inhibitor development
@en
P2093
P2860
P304
P356
10.1111/J.1365-2516.2008.01730.X
P478
14 Suppl 3
P577
2008-07-01T00:00:00Z